Current Problems in Cardiology
Volume 34, Issue 2 , Pages 51-84 , February 2009

Aldosterone and Cardiovascular Disease

References 

  1. Tait JF, Simpson SA, Grundy HM. The effect of adrenal extract on mineral metabolism. Lancet. 1952;1:122–124
  2. Simpson SA, Tait JF, Bush IE. Secretion of a salt-retaining hormone by the mammalian adrenal cortex. Lancet. 1952;2:226–228
  3. Conn JW. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955;45:6–17
  4. Fardella CE, Mosso L, Gomez-Sanchez C, et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab. 2000;85:1863–1867
  5. Lim PO, Dow E, Brennan G, et al. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens. 2000;14:311–315
  6. Mosso L, Carvajal C, Gonzalez A, et al. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42:161–165
  7. Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem. 2005;51:386–394
  8. Gallay BJ, Ahmad S, Xu L, et al. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis. 2001;37:699–705
  9. Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40:892–896
  10. Strauch B, Zelinka T, Hampf M, et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens. 2003;17:349–352
  11. Eide IK, Torjesen PA, Drolsum A, et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens. 2004;22:2217–2226
  12. Umpierrez GE, Cantey P, Smiley D, et al. Primary aldosteronism in diabetic subjects with resistant hypertension. Diabetes Care. 2007;30:1699–1703
  13. Naray-Fejes-Toth A, Fejes-Toth G. The sgk, an aldosterone-induced gene in mineralocorticoid target cells, regulates the epithelial sodium channel. Kidney Int. 2000;57:1290–1294
  14. Funder JW. Aldosterone and mineralocorticoids. In:  Oparil S,  Weber MA editor. Hypertension, A Companion to Brenner and Rector's The Kidney. 2nd edition. Philadelphia, PA: Elsevier; 2005;p. 117–122
  15. Brilla CG, Prick R, Tan LB, et al. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res. 1990;67:1355–1364
  16. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med. 1992;120:893–901
  17. Young M, Fullerton M, Dilley R, et al. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest. 1994;93:2578–2583
  18. Rocha R, Martin-Berger CL, Yang P, et al. Slective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology. 2002;143:4828–4836
  19. Stowasser M. New perspectives on the role of aldosterone excess in cardiovascular disease. Clin Exp Pharmacol Physiol. 2001;28(10):783–791[Review]
  20. Ikeda U, Kanbe T, Nakayama I, et al. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta. Eur J Pharmacol. 1995;290:69–73
  21. Bauersachs J, Heck M, Fraccarollo D, et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol. 2002;39:351–358
  22. Rajagopalan S, Duquaine D, King S, et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation. 2002;105:2212–2216
  23. Blacher J, Amah G, Girerd X, et al. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens. 1997;10:1326–1334
  24. Duprez DA, De Buyzere ML, Rietzschel ER, et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J. 1998;19:1371–1376
  25. Taddei S, Virdis A, Mattei P, et al. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension. 1993;21:929–933
  26. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:594–597
  27. Nishizaka MK, Zaman MA, Green SA, et al. Impaired endothelium-dependant flow mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation. 2004;109:2857–2861
  28. Gokce N, Keaney JF, Hunter LM, et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol. 2003;41:1769–1775
  29. Genest J, Lemieux G, Davignon A, et al. Human arterial hypertension: a state of mild chronic hyperaldosteronism?. Science. 1956;123:503–505
  30. Vasan RS, Evans JC, Larson MG. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351:33–41
  31. Newton-Cheh C, Guo CY, Gona P, et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension. 2007;49:846–856
  32. Grim CE, Cowley AW, Hamet P, et al. Hypertension and hypertension: ethnic differences. Hypertension. 2005;45:766–772
  33. Conn JW, Cohen EL, Rovner DR, et al. Normokalemic primary aldosteronism: a detectable cause of curable “essential” hypertension. JAMA. 1965;193:200–206
  34. Fishman LM, Kuchel O, Liddle GW, et al. Incidence of primary aldosteronism uncomplicated “essential” hypertension (A prospective study with elevated aldosterone secretion and suppressed plasma renin activity used as diagnostic criteria). JAMA. 1968;205:497–502
  35. Gordon RD, Ziesak MD, Tunny TJ, et al. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol. 1993;20(5):296–298
  36. Gordon RD, Stowasser M, Tunny TJ, et al. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol. 1994;21:315–318
  37. Sartori M, Calo LA, Mascagna V, et al. Aldosterone and refractory hypertension: a prospective cohort study. Am J Hypertens. 2006;19:373–379
  38. Ouzan J, Perault C, Lincoff AM, et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens. 2002;1:333–339
  39. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925–930
  40. Mahmud A, Mahgoub M, Hall M, et al. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?. Am J Hypertens. 2005;18:1631–1635
  41. Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839–845
  42. Saha C, Eckert GJ, Amrosius WT, et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension. 2005;46:481–487
  43. Engeli S, Böhnke J, Gorzelniak K, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45:356–362
  44. Goodfriend TL, Ball DL, Gardner HW. An oxidized derivative of linoleic acid affects aldosterone secretion by adrenal cells in vitro. Prostaglandins Leukot Essent Fatty Acids. 2002;67:163–167
  45. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci USA. 2003;100:14211–14216
  46. Calhoun DA, Nishizaka MK, Zaman MA, et al. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest. 2004;25:112–117
  47. Nishizaka MK, Pratt-Ubunama M, Zaman MA, et al. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens. 2005;18:805–812
  48. Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293–2300
  49. Nwariaku FE, Miller BS, Auchus R, et al. Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome. Arch Surg. 2006;141:497–503
  50. Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality (CONSENSUS Trial Study Group). Circulation. 1990;82:1730–1736
  51. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure (Randomized Aldactone Evaluation Study Investigators). N Engl J Med. 1999;341:709–717
  52. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321
  53. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543–551
  54. Beygui F, Collet JP, Benoliel JJ, et al. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation. 2006;114:2604–2610
  55. Rocha R, Chander PN, Khanna K, et al. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension. 1998;31:451–458
  56. Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg. 1964;107:159–172
  57. Irie F, Iso H, Sairenchi T, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int. 2006;69:1264–1271
  58. Tonelli M, Jose P, Curhan G, et al. Cholesterol and Recurrent Events (CARE) Trial Investigators Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ. 2006;332:1426–1429
  59. Fox CS, Larson MG, Hwang S-J, et al. Cross-sectional relations of serum aldosterone and urine sodium excretion to urinary albumin excretion in a community-based sample. Kidney Int. 2006;69:2064–2069
  60. Rossi GP, Bernini G, Desideri G, et al. PAPY Study Participants Renal damage in primary aldosteronism: results of the PAPY study. Hypertension. 2006;48:232–238
  61. Halimi JM, Mimran A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens. 1995;13:1801–1802
  62. Sechi LA, Novello M, Lapenna R, et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA. 2006;295:2638–2645
  63. Ribstein J, Cilar GD, Fesler P, et al. Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol. 2005;16:1320–1325
  64. Pimenta E, Calhoun D. Aldosterone, dietary salt, and renal disease. Hypertension. 2006;48:209–210
  65. Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med. 2006;119:912–919
  66. van den Meiracker AH, Baggen RG, Pauli S, et al. Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function. J Hypertens. 2006;24:2285–2292
  67. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 2005;68:2829–2836
  68. Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006;1:940–951
  69. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421
  70. Bochud M, Nussberger J, Bovet P, et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension. 2006;48:239–245
  71. Kidambi S, Kotchen JM, Grim CE, et al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension. 2007;49:704–711
  72. Fallo F, Veglio F, Bertello C, et al. Prevalence and charecteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2006;91:454–459
  73. Fallo F, Della Mea P, Sonino N, et al. Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens. 2007;20:855–861
  74. Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243–1248

 Drs. Krishna K. Gaddam, Eduardo Pimenta, and Saima Husain have no conflicts of interest to disclose. Dr. David A. Calhoun is Consultant to Astra Zeneca, CV Therapeutics, and Novartis.

PII: S0146-2806(08)00166-7

doi: 10.1016/j.cpcardiol.2008.10.002

Current Problems in Cardiology
Volume 34, Issue 2 , Pages 51-84 , February 2009

Article Tools

* Image Usage & Resolution